Castle Biosciences, Inc.

Castle Biosciences, Inc. Misses on Revenue, Stock Down 0.20%

Castle Biosciences reported an EPS of $0.11, but did not provide revenue figures. The stock reacted slightly down by 0.20%, indicating a cautious sentiment among investors. The lack of guidance and commentary from management may have contributed to the stock's decline, as investors often look for insights on future performance.